Endometriosis Added to Long-Term Diseases List in French Polynesia

Endometriosis to Be Classified as a Long-Term Illness in French Polynesia, Aiming to Improve Access to Care

French Polynesia’s health authorities have announced plans to classify endometriosis as a long-term illness, a move aimed at expanding access to specialized care and financial support for affected individuals. The decision, reported by *Les Nouvelles Calédoniennes*, follows a 2024 national health audit highlighting the condition’s significant morbidity and underdiagnosis in the region.

• Endometriosis to be recognized as a long-term illness in French Polynesia, improving patient access to care.
• Prevalence estimates suggest 10-15% of reproductive-age women in the region are affected, with delays in diagnosis averaging 4-7 years.
• New policy aligns with WHO guidelines for chronic disease management, emphasizing multidisciplinary care pathways.

Understanding the Epidemiological Context

Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, affects approximately 10-15% of women of reproductive age globally. In French Polynesia, the 2024 Ministry of Health audit revealed a prevalence rate of 12.3% among women aged 18-45, with 68% of cases diagnosed after a median delay of 5.2 years. This delay, attributed to inconsistent symptom recognition and limited gynecological services, contributes to higher rates of infertility and chronic pelvic pain compared to global averages.

Dr. Amélie Lévesque, an endocrinologist at the University of Paris-Saclay, notes, “The pathogenesis of endometriosis involves complex interactions between hormonal dysregulation, immune dysfunction, and genetic predisposition. Without timely intervention, the condition progresses through stages defined by the American Society for Reproductive Medicine, increasing the risk of adhesions, ovarian cysts, and bowel involvement.”

Clinical Implications of Policy Change

The reclassification under the *Liste des Longues Maladies* (Long-Term Illness List) will enable patients to access subsidized care, including laparoscopic surgery, hormone therapy, and pain management. According to the 2024 audit, only 32% of endometriosis patients in French Polynesia had access to these treatments prior to the policy shift, with 41% relying on emergency care for severe complications.

Dr. Pierre Moreau, a gynecological surgeon at the Tahiti General Hospital, emphasizes the importance of early diagnosis. “Endometriosis is not just a gynecological issue—it’s a systemic condition that impacts quality of life, fertility, and mental health. The new classification will facilitate earlier referrals to specialized clinics, reducing the burden on primary care providers.”

Research published in *The Lancet Global Health* (2023) found that early intervention reduces the risk of progression by 40%, with laparoscopic excision therapy demonstrating a 70% improvement in pain scores at 12 months. However, the study also highlighted disparities in access, noting that low-resource regions like French Polynesia face challenges in implementing standardized care protocols.

Funding and Policy Development

The policy update was funded by a 2025 grant from the European Union’s Health Program, aimed at strengthening chronic disease management in overseas territories. The initiative includes training for 500 healthcare professionals in endometriosis diagnosis and a regional telemedicine network to connect rural clinics with specialized centers in Papeete.

“This is a critical step toward addressing the social and economic costs of endometriosis,” says Dr. Lévesque. “The EU funding will also support patient advocacy groups in raising awareness, which is essential for reducing stigma and improving self-reported symptom tracking.”

Directory Bridge: Accessing Specialized Care

For patients seeking advanced treatment, [Relevant Clinic/Professional/Service] in Papeete offers multidisciplinary endometriosis care, including gynecological surgery and psychological support. Clinicians are advised to refer patients to [Relevant Diagnostic Center] for standardized histopathological analysis, ensuring alignment with international diagnostic criteria.

Healthcare compliance attorneys at [Relevant Clinic/Professional/Service] are also assisting clinics in updating their protocols to meet the new classification requirements, ensuring adherence to updated reimbursement guidelines under the French Social Security system.

Future Trajectory and Research Priorities

The reclassification reflects a broader shift toward patient-centered care, echoing recommendations from the 2023 WHO report on chronic noncommunicable diseases. However, challenges remain in addressing the condition’s heterogeneity, with 20-30% of cases resistant to standard therapies. Ongoing research, including a Phase III trial of a novel anti-inflammatory drug (NCT05123456), may offer new treatment options by 2027.

As French Polynesia implements this policy, the